Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib plus FLA chemotherapy in paediatric relapsed/refractory KMT2A-r, NUP98-r or NPM1-mut AML
2025-521390-14-00Phase 2Authorised
- Sponsor
- Pediatric Research International
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, single-arm trial of revumenib in acute myeloid leukemia (AML), sponsored by Pediatric Research International. Primary endpoint: Overall response rate (Part I). Planned start Jun 2026; status: authorised.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-521390-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521390-14-00.